Immunitybio Inc

IBRX

7.380USD

0.0000.00%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Immunitybio Inc's Score

Industry at a Glance

Industry Ranking

113 / 391

Overall Ranking

229 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Immunitybio Inc Highlights

StrengthsRisks

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18113.50% year-on-year.

Undervalued

The company’s latest PE is -19.32, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 153.46M shares, increasing 6.08% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 47.20K shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.800

Target Price

+100.54%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Immunitybio Inc is 6.06, ranking 294 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 38.28M, representing a year-over-year increase of 406.95%, while its net profit experienced a year-over-year increase of 4.70%.

Score

Industry at a Glance

Previous score

6.06

Change

0



Financials

4.41

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.79

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.83

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.22

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Immunitybio Inc is 6.22, ranking 308 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.32, which is -94.11% below the recent high of -1.14 and -49.90% above the recent low of -28.96.

Score

Industry at a Glance

Previous score

6.22

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Immunitybio Inc is 8.80, ranking 51 out of 391 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 24.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.80

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Immunitybio Inc is 7.03, ranking 95 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 10.06 and the support level at 5.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.04

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Immunitybio Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 15.58%, representing a quarter-over-quarter increase of 15.29%. The largest institutional shareholder is The Vanguard, holding a total of 32.70M shares, representing 3.18% of shares outstanding, with 38.26% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Cambridge Equities, L.P.

620.25M

+0.91%

The Vanguard Group, Inc.

Star Investors

27.60M

+26.83%

Soon-Shiong (Patrick)

29.55M

-15.98%

BlackRock Institutional Trust Company, N.A.

17.16M

+12.31%

State Street Investment Management (US)

11.32M

+48.59%

Jane Street Capital, L.L.C.

12.84M

+66.30%

Geode Capital Management, L.L.C.

6.89M

+19.26%

Two Sigma Investments, LP

2.75M

+237.27%

Morgan Stanley & Co. LLC

2.79M

+14.48%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Immunitybio Inc is 4.88, ranking 62 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -0.02. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Immunitybio Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Immunitybio Inc

IBRX

6.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment